GFAP and hereditary spastic paraplegia: Although the exact contribution of reactive astrogliosis to HSP remains incompletely understood, these data highlight astrocytes as potential mediators of neurodegeneration and support the use of astrocyte-derived biomarkers—such as GFAP—to quantify glial activation and monitor disease activity in selected HSP phenotypes.